Insulin Analogues: Market Assessment

April 2007

Deliverable Transcripts with key findings

Study Description and Objectives

§    Evaluate the growth in the diabetes market, specifically focused on insulin analogues.  Areas investigated:

o        Choice of product by patient type and other decision drivers

o        Impact of marketing investment (NovoNordisk) or pullback (Eli Lilly)

o        Trends in use of rapid-, short-, intermediate-, and long-acting

o        Trends in use in Type 1 and Type 2 diabetes

o        Competition between long-acting products:

§         Lantus® (insulin glargine [rDNA origin] injection) (Sanofi Aventis)

§         Levemir® (insulin detemir [rDNA origin] injection) (NovoNordisk)

o        Overall trends in next 1-3 years

§    Trends in diabetes treatment outside the insulin analogue class

o        Use of Novartis’ Starlix® (nateglinide)

o        Other novel therapies:  Byetta® (exenatide), Galvus® (vildagliptin), Januvia™ (sitagliptin)

Companies and Products Mentioned in This Report

Inclusion Criteria

Panelists